Clinical trial
SLV308 for Treatment of Patients With Early Parkinson's Disease
NCT00269516 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00269516 |
|---|---|
| Title | SLV308 for Treatment of Patients With Early Parkinson's Disease |
| Official title | A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Early Stage Parkinson's Disease |
| Intervention type | Drug |
| Interventions | pardoprunox, Pardoprunox, Placebo |
| Enrollment | 468 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Aug 29, 2008 |
| Countries | Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand and 9 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: